Short-term treatment with growth hormone stimulates osteoblastic and osteoclastic activity in osteopenic postmenopausal women: a dose response study

Autor: Henning K. Nielsen, Anne Gitte Loft, Moustapha Kassem, Kim Brixen, Leif Mosekilde, Allan Flyvbjerg
Rok vydání: 1995
Předmět:
Procollagen/blood
Deoxypyridinoline
Osteoclasts/cytology
Endocrinology
Diabetes and Metabolism
Bone Development/drug effects
Parathyroid hormone
Osteoclasts
Bone remodeling
chemistry.chemical_compound
Bone Density
Insulin
Orthopedics and Sports Medicine
Insulin-Like Growth Factor I
Osteoporosis
Postmenopausal
Bone mineral
Pyridinoline
Osteocalcin/blood
Middle Aged
Bone Resorption/drug therapy
Bone Diseases
Metabolic/drug therapy
Insulin-Like Growth Factor I/metabolism
Female
Procollagen
medicine.medical_specialty
Thyroid Hormones
Injections
Subcutaneous
Osteocalcin
Bone resorption
N-terminal telopeptide
Calcitriol
Internal medicine
medicine
Humans
Bone Resorption
Calcitriol/blood
Aged
Bone Development
Osteoblasts
Dose-Response Relationship
Drug
business.industry
Osteoporosis
Postmenopausal/drug therapy
Osteoblasts/cytology
Bone Density/drug effects
medicine.disease
Thyroid Hormones/blood
Peptide Fragments
Osteopenia
Bone Diseases
Metabolic
Endocrinology
Growth Hormone/administration & dosage
chemistry
Growth Hormone
Insulin/blood
Peptide Fragments/blood
business
Biomarkers/blood
Biomarkers
Zdroj: Brixen, K, Kassem, M, Nielsen, H K, Loft, A G, Flyvbjerg, A & Mosekilde, L 1995, ' Short-term treatment with growth hormone stimulates osteoblastic and osteoclastic activity in osteopenic postmenopausal women : a dose response study ', Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, vol. 10, no. 12, pp. 1865-74 . https://doi.org/10.1002/jbmr.5650101205
ISSN: 0884-0431
Popis: To investigate the potential use of growth hormone (GH) in Activate-Depress-Free-Repeat treatment of postmenopausal osteoporosis, we measured changes in serum levels of biochemical markers of bone turnover, insulin-like growth factor-I (IGF-I), calciotropic hormones, and bone mineral density in 40 postmenopausal women with osteopenia (ages 52-73 years) in response to 7 days of treatment with either placebo or GH (0.05, 0.10, or 0.20 IU/kg/day) administered subcutaneously in the evening. GH treatment increased serum osteocalcin (p < 0.01) and C-terminal type-I procollagen propeptide (p < 0.01) and also serum levels of type-I collagen telopeptide (p < 0.001), fasting urinary hydroxyproline/creatinine (p < 0.05), pyridinoline/creatinine (p < 0.05), and deoxypyridinoline/creatinine (p < 0.01) in a dose-dependent fashion. Even the lowest dose of GH tested induced a significant increase in these parameters; however, the effects were transient lasting only 1-2 weeks. In the highest dose group, however, a somewhat prolonged effect (30 days) on serum osteocalcin was observed. Furthermore, GH increased serum levels of IGF-I, insulin, and tri-iodothyronin. No effect on serum 1,25-dihydroxyvitamin D3 or parathyroid hormone could be demonstrated. Adverse effects were mainly related to fluid retention. They were clearly dose-dependent and rapidly reversible. In conclusion, short-term GH treatment stimulates bone formation and bone resorption in postmenopausal women with osteopenia.
Databáze: OpenAIRE
Externí odkaz: